User reviews

User Review - Flag as inappropriate

enzastaurin (LY317615) prevent smokers randomized study of lung cancer two
Before the test, the survey found that this drug in precancerous lesions and early lung cancer to inhibit PKC-β pathway
and interference effects. In the intent to treat analysis, 40 randomized participants prior to treatment / treatment Ki-67 LI changes in enzastaurin and placebo groups there was no significant difference (P = 0.53). 6 subjects discontinued use of <a href="">enzastaurin</a>, including 4 adverse events, including bloating, deep vein thrombosis, hyponatremia, and rash; 2 participants decided to terminate the test. 1 subjects stopped because of poor compliance with placebo. Two subjects had ≥ 1 serious adverse event entries (bradycardia, deep vein thrombosis and hypotension).
Medchemexpress Can provide the above product,its website:<a href=""></a>
<a href="">E-3810</a>
<a href="">TG 100572 Hydrochloride</a>
<a href="">TG 100801</a>
<a href="">TG 100801 Hydrochloride</a>
<a href="">BMS-690514</a>
<a href="">Apatinib</a>
<a href="">Navitoclax</a>
<a href="">Obatoclax</a>
<a href="">HA14-1</a>
<a href="">TW-37</a>

All reviews - 1
5 stars - 0
4 stars - 0
3 stars - 0
2 stars - 0
1 star - 0

All reviews - 1
Editorial reviews - 0